Status:
COMPLETED
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Lead Sponsor:
Pfizer
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
18-90 years
Brief Summary
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical ...
Detailed Description
Eligible patients in routine clinical practice
Eligibility Criteria
Inclusion
- adults with neovascular age-related macula degeneration
Exclusion
- according to SmPC
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00858208
Start Date
March 1 2008
End Date
April 1 2011
Last Update
April 11 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Pátrai, Pellopoese, Greece
2
Pfizer Investigational Site
Alexandroupoli, Greece
3
Pfizer Investigational Site
Athens, Greece, 12462
4
Pfizer Investigational Site
Athens, Greece